A facile adenosine triphosphate‑responsive nanoplatform for efficacious therapy of esophageal cancer

Wang,Jinglong; Xu,Linhao; Liu,Xiaotong; Yang,Ronghua; Wang,Dong

doi:10.3892/ol.2020.11969

A facile adenosine triphosphate‑responsive nanoplatform for efficacious therapy of esophageal cancer

Authors:
- Jinglong Wang
- Linhao Xu
- Xiaotong Liu
- Ronghua Yang
- Dong Wang
View Affiliations

Affiliations: Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China
Published online on: August 10, 2020 https://doi.org/10.3892/ol.2020.11969
Article Number: 108
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Current chemotherapeutic agents against esophageal cancer (EC) are suboptimal. To improve treatment efficacy, a nanoplatform based on ATP‑responsive drug release was developed for EC therapy. First, the chemotherapeutic agent epirubicin (EPI) was inserted into an ATP aptamer (Ap) to form double‑stranded DNA (‘DNA duplex’). Subsequently, polyethyleneimine (PEI) was employed to condense the EPI‑loaded duplex to construct the final nanoplatform (PEI‑Ap‑EPI). Following internalization by cancer cells, the EPI‑loaded DNA duplex could open and release EPI in an intracellular ATP‑rich environment. An in vitro drug‑release assay demonstrated that ~50% of EPI was released from PEI‑Ap‑EPI in an ATP‑rich condition. However, only 15% of EPI was released in the presence of a low concentration of ATP. In vitro cytotoxicity and apoptosis assays demonstrated that PEI‑Ap‑EPI could enhance EPI efficiency against EC cells markedly compared with those in the control group. Therefore, this facile PEI‑Ap‑EPI nanoplatform may be a promising strategy to improve the efficacy of EPI treatment in EC.

View Figures

View References

1	Pakzad R, Mohammadian-Hafshejani A, Khosravi B, Soltani S, Pakzad I, Mohammadian M, Salehiniya H and Momenimovahed Z: The incidence and mortality of esophageal cancer and their relationship to development in Asia. Ann Transl Med. 4:292016.PubMed/NCBI
2	Bandla S, Pennathur A, Luketich JD, Beer DG, Lin L, Bass AJ, Godfrey TE and Litle VR: Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann of Thorac Surg. 93:1101–1106. 2012. View Article : Google Scholar
3	Zhang HZ, Jin GF and Shen HB: Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer. 31:281–286. 2012. View Article : Google Scholar : PubMed/NCBI
4	Crane SJ, Locke GR III, Harmsen WS, Zinsmeister AR, Romero Y and Talley NJ: Survival trends in patients with gastric and esophageal adenocarcinomas: A population-based study. Mayo Clin Proc. 83:1087–1094. 2008. View Article : Google Scholar : PubMed/NCBI
5	Fan Z, Chang Y, Cui C, Sun L, Wang DH, Pan Z and Zhang M: Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy. Nat Commun. 9:26052018. View Article : Google Scholar : PubMed/NCBI
6	Liu Y, Zhang B and Yan B: Enabling anticancer therapeutics by nanoparticle carriers: The delivery of Paclitaxel. Int J Mol Sci. 12:4395–4413. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wen H, Jung H and Li X: Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges. Aaps J. 17:1327–1340. 2015. View Article : Google Scholar : PubMed/NCBI
8	Greish K: Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 624:25–37. 2010. View Article : Google Scholar : PubMed/NCBI
9	Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, et al: Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology. 16:712018. View Article : Google Scholar : PubMed/NCBI
10	Mo R and Gu Z: Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery. Mater Today. 19:274–283. 2016. View Article : Google Scholar
11	Zhang X, Ren X, Tang J, Wang J, Zhang X, He P, Yao C, Bian W and Sun L: Hyaluronic acid reduction-sensitive polymeric micelles achieving co-delivery of tumor-targeting paclitaxel/apatinib effectively reverse cancer multidrug resistance. Drug Deliv. 27:825–835. 2020. View Article : Google Scholar : PubMed/NCBI
12	Mo R, Jiang T, DiSanto R, Tai W and Gu Z: ATP-triggered anticancer drug delivery. Nat Commun. 5:33642014. View Article : Google Scholar : PubMed/NCBI
13	Tan Y, Shi YS, Wu XD, Liang HY, Gao YB, Li SJ, Zhang XM, Wang F and Gao TM: DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro. Acta Pharmacol Sin. 34:1491–1498. 2013. View Article : Google Scholar : PubMed/NCBI
14	Huizenga DE and Szostak JW: A DNA aptamer that binds adenosine and ATP. Biochemistry. 34:656–665. 1995. View Article : Google Scholar : PubMed/NCBI
15	Modh H, Witt M, Urmann K, Lavrentieva A, Segal E, Scheper T and Walter JG: Aptamer-based detection of adenosine triphosphate via qPCR. Talanta. 172:199–205. 2017. View Article : Google Scholar : PubMed/NCBI
16	Heilkenbrinker A, Reinemann C, Stoltenburg R, Walte JG, Jochums A, Stahl F, Zimmermann S, Strehlitz B and Scheper T: Identification of the target binding site of ethanolamine-binding aptamers and its exploitation for ethanolamine detection. Anal Chem. 87:677–685. 2015. View Article : Google Scholar : PubMed/NCBI
17	Canzoneri JC and Oyelere AK: Interaction of anthracyclines with iron responsive element mRNAs. Nucleic Acids Res. 36:6825–6834. 2008. View Article : Google Scholar : PubMed/NCBI
18	Takeda K, Uchiyama K, Kinukawa M, Tagami T, Kaneda M and Watanabe S: Evaluation of sperm DNA damage in bulls by TUNEL assay as a parameter of semen quality. J Reprod Dev. 61:185–190. 2015. View Article : Google Scholar : PubMed/NCBI
19	Guo JR, Chen QQ, Lam CW and Zhang W: Effects of karanjin on cell cycle arrest and apoptosis in human A549, HepG2 and HL-60 cancer cells. Biol Res. 48:402015. View Article : Google Scholar : PubMed/NCBI
20	Dizaj SM, Jafari S and Khosroushahi AY: A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Res Lett. 9:2522014. View Article : Google Scholar : PubMed/NCBI
21	Wang L, Lin X, Wang J, Hu Z, Ji Y, Hou S, Zhao Y, Wu X and Chen C: Novel insights into combating cancer chemotherapy resistance using a plasmonic nanocarrier: Enhancing drug sensitiveness and accumulation simultaneously with localized mild photothermal stimulus of femtosecond pulsed laser. Adv Funct Mater. 24:4229–4239. 2014. View Article : Google Scholar
22	Blanco E, Shen H and Ferrari M: Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 33:941–951. 2015. View Article : Google Scholar : PubMed/NCBI
23	Akinc A, Thomas M, Klibanov AM and Langer R: Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med. 7:657–663. 2005. View Article : Google Scholar : PubMed/NCBI
24	Liu Y, Xu CF, Iqbal S, Yang XZ and Wang J: Responsive nanocarriers as an emerging platform for cascaded delivery of Nucleic acids to cancer. Adv Drug Deliv Rev. 115:98–114. 2017. View Article : Google Scholar : PubMed/NCBI